Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1644-1649

  Schmidt, E ^a   Thoennissen, N H ^a   Rudat, A ^a   Bieker, R ^a   Schliemann, C ^a   Mesters, R M ^a   Zuhlsdorf M ^a   Muller Tidow C ^a   Berdel, W E ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Methotrexate; Oral mucositis; Palifermin

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DEXPANTHENOL; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MORPHINE; PALIFERMIN; PREDNISOLONE; RITUXIMAB; TETRACAINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; HUMAN; INFECTION; MOUTH INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORAL MUCOSITIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 50849122647     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn179     Document Type: Article

References (30)

1. Sonis ST. Mucositis as a biological process: A new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34: 39-43.
2. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-284.
3. Sonis ST, Elting LS, Keefe D et al. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100(9 Suppl): 1995-2025.
4. Sonis ST. The biological role of nuclear factor - kappaB in disease and its potential involvement in mucosal injury associated with antineoplastic therapy. Crit Rev Oral Biol Med 2002; 13: 380-389.
5. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis 2006; 12: 229-241.
6. Ruescher TJ, Sodeifi A, Scrivani SJ et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82: 2275-2281.
7. Costa SF, Miceli MH, Anaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia? Lancet Infect Dis 2004; 4: 278-286.
8. Sezer O, Eucker J, Metzner B et al. Mucositis is associated with increased rate of documented infections and treatment related mortality after high-dose therapy and autologous peripheral stem-cell transplantation. Proc Am Soc Clin Oncol 2000; 19: 56a (Abstr 216).
9. Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19: 2201-2205.
10. Elting LS, Shih YT, Stiff PJ et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoetic stem-cell transplant: Analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007; 13: 806-813.
11. Fanning SR, Rybicki L, Kalaycio M et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 2006; 135: 374-381.
12. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007; 109: 820-831.
13. Dumontet C, Sonnet A, Bastion Y et al. Prevention of high-dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant 1994; 14: 492-494.
14. Edelman MJ, Gandara D, Perez EA et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: Amelioration of dose-limiting mucositis by ice chip cryotherapy. Invest New Drugs 1998; 16: 69-75.
15. Kuhrer I, Kuzmits R, Linkesch W et al. Topical PGE2 enhances healing of chemotherapy-associated mucosal lesions. Lancet 1986; 1: 623.
16. Farrell CL, Rex KL, Chen JN. The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 2002; 35 (Suppl 1): S78-S85.
17. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Eng J Med 2004; 351(25): 2590-2598.
18. Oelmann E, Haghgu S, Kulimova E et al. Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-flourouracil in vitro. Int J Oncol 2004; 25: 1001-1012.
19. Krijanovski OL, Hill GR, Cooke KR et al. Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 1999; 94: 825-831.
20. Ellison CA, Natulik SA, Fischer JM et al. Effect of recombinant human keratinocyte growth factor (rHuKGF) on the immunopathogenesis of intestinal graft-vs.-host disease induced without preconditioning regimen. J Clin Immunol 2004; 24: 197-211.
21. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): A pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18: 817-826.
22. Braun S, Hanselmann C, Gassmann MG et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002; 22: 5492-5505.
23. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
24. Hoelzer D, Baur KH, Giagounidis A et al. Short intensive chemotherapy with rituximab seems successful in Burkitt NHL, mature B-ALL and other high grade B-NHL. Blood 2003: 102 (Abstr 236).
25. Reiter A, Schrappe M, Zimmermann M et al. A 4-hour i.v. infusion of methotrexate 5 g/sqm is not as efficacious for treatment of advanced B-cell neoplasms of childhood and adolescence than 24 hour i.v. infusion although less toxic. Interim results of trial NHL-BFM 95. Blood 2001: 98 (11 Part 1).
26. Hölzer D, Ludwig WD, Thiel E et al. Improved outcome in adult B-cell lymphoblastic leukemia. Blood 1996; 87: 495-508.
27. Rosen LS, Abdi E, Davis ID et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006; 24: 5194-5200.
28. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. The Cochrane Library 2007; (4).
29. Freytes CO, Ratanatharathorn V, Taylor C et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous stem cell transplantation. Clin Cancer Res 2004; 10(24): 8318-8324.
30. Merepol NJ, Somer RA, Gutheil J et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21(8): 1452-1458.